August 2012
-
ARS Pharmaceuticals has announced results from the EPI-04 clinical study demonstrating that the company’s ARS-1 intranasal epinephrine spray has a pharmacokinetic profile that is similar to intramuscular epinephrine. ARS is developing ARS-1 for the treatment… Read more . . .
-
The Brazilian Health Regulatory Agency (ANVISA) has approved Afrezza inhaled insulin for the treatment of diabetes, and the DPI is expected to be launched in Brazil by the end of 2019, MannKind Corporation said. MannKind announced… Read more . . .
-
Clement Clarke has announced the launch of its Clip-Tone technique guidance whistle for use with GSK’s Evohaler Ventolin and Seretide MDIs in the UK. The Clip-Tone will be available by prescription only. Like the company’s… Read more . . .
-
Novartis has announced that the Phase 3 QUARTZ study met its primary and secondary endpoints, demonstrating that low dose QMF149 indacaterol/mometasone furoate delivered via the Breezhaler DPI produced statistically significant and clinically meaningful lung function… Read more . . .
-
Nasal drug delivery specialist Kurve Technology announced that the US Department of Defense (DoD) has awarded the company a contract for testing a formulation for the treatment of traumatic brain injury (TBI). The Kurve ViaNase… Read more . . .
-
Submit 500-word poster abstracts by August 31 at http://inhalationasia.org/conference/inhalation-asia-19/present Please note that according to the organizers, “ALL authors agree to make their abstracts and a copy of their poster or presentation available for free to… Read more . . .
-
DPI developer TFF Pharmaceuticals said that is has raised $8.17 million through a Series A preferred stock offering and that it will use the funds for R&D. In April 2018, the company announced that it… Read more . . .
-
Acerus Pharmaceuticals said that it has acquired exclusive worldwide rights to technology related to intranasal delivery of testosterone from the University of Texas at Austin. The company said that the agreement covers the use of… Read more . . .
-
According to BlueWillow Biologics, the University of Michigan has been issued US patent No. 10,138,279 which covers an intranasal anthrax vaccine formulated with BlueWillow’s NanoVax adjuvant. BlueWillow (formerly NanoBio) is a spin out from the University… Read more . . .
-
Nanonization company Nanoform has named former Hovione Senior Project Manager Miguel Cansado as Director of Project Management. Cansado is the third former Hovione employee to join Nanoform this year, following the appointments of Miguel Calado… Read more . . .
Featured event:
5th Annual Inhaled & Nasal Biologics | DNA Forum
5th Annual Inhaled & Nasal Biologics | DNA Forum
24th-25th September 2026, Cambridge, UK
Join us for a ground-breaking and insightful forum: Two days of cutting-edge talks and networking opportunities in this complex area of drug and vaccine development.
With renowned industry leaders who will share their insights and real-world case studies, our speakers will explore innovative formulation and delivery technologies and the rationale behind overcoming development challenges. Don’t miss out on this opportunity to learn more about key topics shaping the future of inhaled therapeutics.
Get online to see speakers announced so far. Registration is live – save your seat now!
Upcoming Events
Sponsored by Intertek,, hosts of
The Inhaled & Nasal Biologics | DNA Forum
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
No events are found.